Gastric Lipase Enhanced Nasogastric Tube Study in Neonates

February 28, 2023 updated by: Imperial College London

A Diagnostic Accuracy Study Evaluating Point of Care Gastric Lipase Enhanced pH Test Strip to Confirm Correct Nasogastric Tube Position in Newborn Infant

The newborn infants who are sick and those who are born prior to due date (preterm) are admitted to the neonatal unit. These babies are unable to feed through their mouth, so a special tube is passed through their nose to the stomach, nasogastric (NG) tube) to provide milk feeds. The bedside nurse inserts the tube and then aspirate some of the fluid from the stomach. As the stomach normally produce acid, these aspirate is then tested on a colour coded paper strip to check if the fluid is acidic. However, on many occasions this test is not very clear. This could be due to misplacement of the tube or the stomach in a newborn not being able to produce enough acid. This then leads to re-siting of another tube and following the same procedure. Sometimes the clinical team may like to do an X Ray to check the position of the tube resulting in unnecessary exposure to radiation. The study will use a special chemical added to the currently existing paper test strip which the investigators believe will enhance the capability of detecting the correct position of the NG tube. This idea has been tested in adults and found to have increased the sensitivity of the test strip significantly. Based on the adult study the study will require to test 233 babies to see if this increases the sensitivity of correct NG tube placement. Parents of all babies who requires an NG tube for milk feeds will be approached and after appropriate consent could be recruited to the study. Babies who are clinically very unstable, moribund and those with diagnosis of bowel obstruction will be excluded from the study.

Study Overview

Status

Completed

Conditions

Detailed Description

STUDY OBJECTIVES

Primary Objective:

• To determine the sensitivity of the chemical (tributyrin) impregnated pH test strip in comparison to the routine pH test strip to increase the sensitivity of detection of correct positioning of the nasogastric tube

Secondary objectives:

  • To measure the number of nasogastric tube re-insertion attempts that could be avoided if the tributyrin impregnated pH test strip was used instead of the standard pH test strip
  • To determine the number of chest radiographs which could be avoided if the tributyrin impregnated pH test strip was used instead of the standard pH test strip
  • To carry out human factors assessment of perceived usability, trust and acceptance of the lipase-based pH test strip

STUDY DESIGN Prospective point of care diagnostic accuracy study

Primary outcome

• Sensitivity of proposed test in determining correct nasogastric (NG) tube position

Secondary outcomes

  • Number of chest x rays performed
  • Time to confirm tube placement
  • Number of nasogastric tube attempts to get the correct pH
  • Assessment of human factors - Perceived usability, trust and acceptance from professionals' perspective

Subject selection and setting

Participants will be recruited from Imperial College Healthcare NHS Trust from the neonatal units at both the Queen Charlotte's and Chelsea and St. Mary's hospital sites. Eligible participants will be identified by the clinical team and recruited by a member of the research team.

The vast majority of admitted infants will require nasogastric tube insertion as part of their clinical management such as preterm infants, sick term infants with hypoxic- ischaemic encephalopathy and meconium aspiration syndrome as well as admitted infants for hypoglycaemia and jaundice management.

Study method

The clinical trial will be a diagnostic accuracy study of two diagnostic tests and will be reported in accordance with the Standards for reporting diagnostic accuracy studies (STARD) guidelines. The index tests will be (i) the novel tributyrin impregnated pH test strip and (ii) standard pH test strip. The reference test used for comparison will be chest x-ray performed earlier or later but with the same nasogastric tube in situ; or where this is not required 'trial by use' (any chest x-rays undertaken would be decided and authorised by the participant's clinical team who are clearly separated from the research team. Undergoing a chest x-ray does not from part of screening for the study and is not a requirement of the study protocol).

Ingenza novel lipase/pH test strip

The test detects the organic acid released from tributyrin, a chemical ester impregnated onto pH paper by the action of human gastric lipase that is stable in gastric juice and resistant towards antacid medications, as well as unlikely to migrate. Ingenza have impregnated enteral pH indicator strips that are in current clinical use with emulsion formulations of tributyrin, protected by intellectual property as human gastric lipase substrates. Therefore, the novel test strips will provide a positive result in the presence of an acidic environment (pH less than or equal to 5.5) or gastric lipase.

Index testing

After the tube insertion, the carer will aspirate the tube to obtain a sample of gastric fluid. This will be done immediately following insertion or as part of daily position confirmation that is routinely performed prior to initiation of nasogastric feeding. The aspirate will be used by the healthcare professional, as part of routine care and the remaining sample passed to a member of the research team. The healthcare professional will test the aspirate routinely and make their decision based on the current standard pH strip test. The remaining sample will be used by the research nurse blinded to the standard test, to wet the gastric lipase enhanced pH test strip. The research nurse will then independently assess the results of the study test paper at two minutes. Digital photographs of both the routine and the study test papers will be assessed independently by member of the study team to verify the findings. The healthcare professional will be blinded to the results of the proposed test strip. The research nurse will record the results of the standard test strip only after documenting the result of the proposed test.

For standard pH strips a pH of ≤5.5 will indicate correct tube placement and >5.5 indicates incorrect nasogastric tube position. For the gastric lipase enhanced pH strip test a positive result will be determined according to the manufacturer's recommendations.

INCLUSION CRITERIA

All infants (preterm and term) who require the insertion of nasogastric tubes for supplementary enteral feeding as part of their routine clinical management

EXCLUSION CRITERIA

Clinically unstable, critically ill infants Infants undergoing palliative care Infants with bowel conditions such as necrotising enterocolitis, bowel obstruction

Study Type

Observational

Enrollment (Actual)

233

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • London, United Kingdom
        • Imperial College Healthcare NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 3 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All infants admitted to the neonatal unit requiring insertion of nasogastric tube

Description

Inclusion Criteria:

  • All infants (preterm and term) who require the insertion of nasogastric tubes for supplementary enteral feeding as part of their routine clinical management

Exclusion Criteria:

  • Clinically unstable, critically ill infants
  • Infants undergoing palliative care
  • Infants with bowel conditions such as necrotising enterocolitis, bowel obstruction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensitivity of standard and ingenza pH strips
Time Frame: 6 months
Where test sensitivity is defined as the proportion of pH readings that are equal to or below (<=) a certain cut-off when aspirates are obtained from tubes placed inside the stomach. Stomach placements are confirmed either by chest x-rays, or in its absence, by clinical observations).
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of chest x rays performed
Time Frame: 6 months
Number of chest X Rays performed to confirm nasogastric tube position after insertion and failure of detection of position using currently available pH measurement strips
6 months
Time to confirm tube placement
Time Frame: 6 months
Total time in minutes to confirm nasogastric tube position
6 months
Number of nasogastric tube attempts to get the correct pH
Time Frame: 6 months
Number of nasogastric tube attempts to get the correct pH
6 months
Specificity of standard and ingenza pH strips
Time Frame: 6 months
Where test specificity is defined as the proportion of pH readings that are greater than (>) a certain cut-off when aspirates are obtained from tubes placed outside the stomach. Non-stomach placements are confirmed by chest x-rays or through reported adverse events.
6 months
pH readings obtained by standard and ingenza strips under all cut-offs
Time Frame: 6 months
pH readings obtained by standard and ingenza strips under all cut-offs
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 2, 2020

Primary Completion (Actual)

December 30, 2021

Study Completion (Actual)

December 30, 2021

Study Registration Dates

First Submitted

February 13, 2020

First Submitted That Met QC Criteria

February 13, 2020

First Posted (Actual)

February 17, 2020

Study Record Updates

Last Update Posted (Actual)

March 1, 2023

Last Update Submitted That Met QC Criteria

February 28, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 19QC5444

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neonatal Disorder

Subscribe